Experiences from treatment-predictive KRAS testing; High mutation frequency in rectal cancers from females and concurrent mutations in the same tumor

BMC Clinical Pathology

Volumn 9, Issue 1, 2009, Pages

  Jönsson, Mats ^a   Ekstrand, Anna ^a   Edekling, Thomas ^b   Eberhard, Jakob ^a   Grabau, Dorthe ^a   Borg, David ^a   Nilbert, Mef ^a,c  

^a LUND UNIVERSITY   (Sweden)

^b Vaxjo County Hospital   (Sweden)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID DERIVATIVE; CYSTEINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GLYCINE DERIVATIVE; VALINE;

ADULT; AGED; ARTICLE; CANCER PATIENT; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; EXPERIENCE; FEMALE; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; OBSERVATIONAL STUDY; ONCOGENE K RAS; PREDICTION; REAL TIME POLYMERASE CHAIN REACTION; RECTUM CANCER; TUMOR GROWTH;

EID: 70449441671     PISSN: 14726890     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-9-8     Document Type: Article

References (17)

1. Genetic alterations in the adenoma-carcinoma sequence. KR Cho B Vogelstein, Cancer 1992 70 1727 31 10.1002/1097-0142(19920915)70:4+<1727:: AID-CNCR2820701613>3.0.CO;2-P 1516027
2. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. H Lindarou J Dahabreh D Kanaloupiti F Siannis D Bafaloukos P Kosmidis CA Papadimitriou S Murray, Lancet Oncol 2008 9 962 72 10.1016/S1470-2045(08)70206-7 18804418
3. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. CJ Allegra JM Jessup MR Somerfield SR Hamilton EH Hammond DF Hayes PK McAllister RF Morton RL Schilsky, J Clin Oncol 2009 27 2091 6 10.1200/JCO.2009.21.9170 19188670
4. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance programme. JHJM Van Krieken A Jung T Kirchner, et al. Virchow Arch 2008 453 417 31 10.1007/s00428-008-0665-y
5. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. S Ogino T Kawasaki M Brahmandam S Ogino T Kawasaki M Brahmandam L Yan M Cantor C Namgyal M Mino-Kenudson GY Lauwers M Loda CS Fuchs, J Mol Diagn 2005 7 413 21 16049314
6. Kirsten ras mutation sin patients with colorectal cancer: the "RASCAL II" study. HJN Andreyev AR Norman D Cunningham, et al. Br J Cancer 2001 85 692 6 10.1054/bjoc.2001.1964 11531254
7. Are there two sides to colorectal cancer? B Iacopetta, Int J Cancer 2002 101 403 8 10.1002/ijc.10635 12216066
8. K-ras oncogene mutations in sporadic colorectal cancer in the Netherlands cohort study. M Brink FPM de Goeij MP Weijenberg M Brink MP Weijenberg AF De Goeij LJ Schouten FD Koedijk GM Roemen MH Lentjes AP De Brune RA Goldbohm PA Van Den Brandt, Carcinogenesis 2003 24 703 10 10.1093/carcin/bgg009 12727799
9. Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. R Yantiss M Goodarzi X Zhou H Rennert EC Pirog BF Banner YT Chen, Am J Surg Pathol 2009 33 572 82 10.1097/PAS.0b013e31818afd6b 19047896
10. Letter to the editor. S Gattenlohner C Germer H-K Muller-Hermelink, N Engl J Med 2009 380 835
11. Chromosomal changes in colorectal adenomas: relationship to gene mutations and potential for clinical utility. A Leslie A Stewart DU Baty, et al. Genes Chrom Cancer 2006 45 126 35 10.1002/gcc.20271 16235243
12. APC and the three-hit hypothesis. S Segditas AJ Rowan K Howarth, et al. Oncogene 2009 28 146 55 10.1038/onc.2008.361 18836487
13. Concurrent mutations of K-ras oncogene at codons 12 and 22 in colon cancer. Y Miyakura K Sugano N Fukayama F Konishi H Nagai, Jpn J Clin Oncol 2002 32 219 21 10.1093/jjco/hyf043 12110640
14. Frequency and clinicopathology associations of K-ras mutations in colorectal cancer in a northeast Mexican population. SG Martinez-Garza AJ Nunez-Salazar AL Calderon-Garciduenas FJ Bosques-Padilla A Niderhauser- García HA Barrera-Saldãa, Dig Dis 1999 17 225 9 10.1159/000016940 10754362
15. Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. P Moerkerk JW Arends M van Driel A de Bruine A de Goeij J ten Kate, Cancer Res 1994 54 3376 8 8012953
16. Structural differences between Valine-12 and Aspartate-12 Ras proteins may modify carcinoma aggression. F Al-Mulla EJ Milner-White J Going G Birnie, J Pathology 1999 187 433 38 10.1002/(SICI)1096-9896(199903)187:4<433::AID- PATH273>3.0.CO;2-E
17. Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context. M Monticone E Biollo M Maffei A Donadini F Romeo CT Storlazzi W Giaretti P Castagnla, Mol Cancer 2008 7 92 10.1186/1476-4598-7-92 19087308